<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Carmustine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Carmustine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Carmustine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11180" href="/d/html/11180.html" rel="external">see "Carmustine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13118" href="/d/html/13118.html" rel="external">see "Carmustine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708652"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Myelosuppression (injection)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Carmustine causes suppression of marrow function (including thrombocytopenia and leukopenia), which may contribute to bleeding and overwhelming infections. Monitor blood counts weekly for at least 6 weeks after each dose. Adjust dosage based on nadir blood counts from the prior dose. Do not administer a repeat course of carmustine until blood counts recover.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pulmonary toxicity (injection)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Carmustine causes dose-related pulmonary toxicity. Patients receiving greater than 1,400 mg/m<sup>2</sup> cumulative dose are at significantly higher risk than those receiving less. Delayed pulmonary toxicity can occur years after treatment, and can result in death, particularly in patients treated in childhood.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F146512"><span class="drugH1">Brand Names: US</span>
<ul>
<li>BiCNU [DSC];</li>
<li>Gliadel Wafer</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866206"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>BiCNU</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F146552"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Alkylating Agent;</li>
<li>
                        Antineoplastic Agent, Alkylating Agent (Nitrosourea)</li></ul></div>
<div class="block doa drugH1Div" id="F146516"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Carmustine (IV) is associated with a high emetic potential; antiemetics are recommended to prevent nausea and vomiting (ASCO [Hesketh 2020]; MASCC/ESMO [Roila 2016]). Platelet counts should be &gt;100,000/mm<sup>3</sup>, ANC &gt;1,000/mm<sup>3</sup>, and leukocytes &gt;4,000/mm<sup>3</sup> prior to a repeat course. Repeat courses should not be administered more frequently than every 6 weeks.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f17c9c0a-c295-46fa-aebe-4892e92ef957">Central nervous system tumors, primary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Central nervous system tumors, primary:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Glioma, recurrent (off-label dose): IV:</b> 80 mg/m<sup>2</sup> on days 1, 2, and 3 every 8 weeks for a maximum of 6 cycles (Brandes 2004; Reithmeier 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Glioma, malignant, newly diagnosed (off-label dose): IV:</b> 200 mg/m<sup>2</sup> every 8 weeks (up to a maximum cumulative dose of 1,500 mg/m<sup>2</sup>) (Selker 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Wafer implants:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Glioma, newly diagnosed high-grade:</b>
<b>Implantation (wafer):</b> 8 wafers (7.7 mg each) implanted intracranially into the resection cavity (total dose 61.6 mg); should the size and shape not accommodate 8 wafers, the maximum number of wafers feasible (up to 8) should be placed.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Glioblastoma, recurrent:</b>
<b>Implantation (wafer): </b>8 wafers (7.7 mg each) implanted intracranially into the resection cavity (total dose 61.6 mg); should the size and shape not accommodate 8 wafers, the maximum number of wafers feasible (up to 8) should be placed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b5574180-026c-4fd1-b545-aabeb32c654f">Hematopoietic cell or bone marrow transplant conditioning regimen</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic cell or bone marrow (autologous) transplant conditioning regimen (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">BEAM regimen: <b>IV: </b>300 mg/m<sup>2</sup> as a single dose 6 days prior to transplant (in combination with etoposide, cytarabine, and melphalan) (Chopra 1993; Geisler 2008; Linch 2010; Mills 1995).</p>
<p style="text-indent:-2em;margin-left:4em;">BEAC regimen: <b>IV: </b>300 mg/m<sup>2</sup> as a single dose 6 days prior to transplant (in combination with etoposide, cytarabine, and cyclophosphamide) (Geisler 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">CBV regimen: <b>IV: </b>600 mg/m<sup>2</sup> as a single dose 3 days prior to transplant (in combination with cyclophosphamide and etoposide) (Reece 1991).</p>
<p style="text-indent:-2em;margin-left:4em;">Carmustine/thiotepa regimen (primary CNS lymphoma): <b>IV: </b>400 mg/m<sup>2</sup> as a single dose 6 days prior to transplant (in combination with thiotepa) (Ferreri 2016; Illerhaus 2008; Kasenda 2012). Refer to protocols for specific details.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3d5bcca0-516c-49f9-9ff4-3868125ce80c">Hodgkin lymphoma, relapsed or refractory, salvage therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, relapsed or refractory,</b>
<b> salvage therapy (off-label dose):</b> Mini-BEAM regimen: <b>IV:</b> 60 mg/m<sup>2</sup> on day 1 every 4 to 6 weeks (in combination with etoposide, cytarabine, and melphalan) for 2 to 4 cycles, followed by conditioning for autologous transplant in responders (Colwill 1995; Martin 2001).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="52e3fc65-3b87-4044-ae08-339520ab37e8">Mycosis fungoides, early stage, topical</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mycosis fungoides, early stage, topical (off-label use/route):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Ointment (10 mg/100 grams petrolatum): <b>Topical: </b>Apply once daily to affected areas (Zackheim 2003).</p>
<p style="text-indent:-2em;margin-left:4em;">Solution (10 mg/60 mL water): <b>Topical: </b>Apply once daily to affected areas (Zackheim 2003).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992082"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Manufacturer’s labeling: CrCl &lt;10 mL/minute: Discontinue treatment. Do not administer to patients with compromised kidney function.</p>
<p style="text-indent:-2em;margin-left:2em;">The following dosage adjustments have also been reported:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 46 to 60 mL/minute: Reduce dose to 80% of the usual dose (Kintzel 1995; Krens 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 31 to 45 mL/minute: Reduce dose to 75% of the usual dose (Kintzel 1995; Krens 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≤30 mL/minute: Use is not recommended; consider use of alternative drug (Kintzel 1995; Krens 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Use is not recommended (Krens 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Wafer implant:</b> There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50989281"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> There are no dosage adjustments provided in the manufacturer’s labeling. The following recommendations have been reported:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild or moderate impairment: No need for dose adjustment is expected (Krens 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use is not recommended (Krens 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Wafer implant:</b> There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doo drugH1Div" id="F20344387"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup> (<b>Note:</b> Excludes hematopoietic cell transplantation dosing):</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full, weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (ASCO [Griggs 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>American Society for Blood and Marrow Transplantation practice guideline committee position statement on chemotherapy dosing in obesity:</i> Utilize actual body weight for calculation of BSA in carmustine dosing for hematopoietic cell transplant conditioning regimens in adult patients weighing ≤120% of their ideal body weight (IBW). In patients weighing &gt;120% IBW, utilize adjusted body weight 25% (ABW25) to calculate BSA (ASBMT [Bubalo 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">ABW25: Adjusted wt (kg) = Ideal body weight (kg) + 0.25 [actual wt (kg) - ideal body weight (kg)]</p></div>
<div class="block dot drugH1Div" id="F12855270"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Carmustine IV: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hematologic toxicity:</b> Based on nadir counts with previous dose (manufacturer’s labeling). IV:</p>
<p style="text-indent:-2em;margin-left:6em;">If leukocytes ≥3,000/mm<sup>3</sup> and platelets ≥75,000/mm<sup>3</sup>: Administer 100% of carmustine dose.</p>
<p style="text-indent:-2em;margin-left:6em;">If leukocytes 2,000 to 2,999/mm<sup>3</sup> or platelets 25,000 to 74,999/mm<sup>3</sup>: Reduce dose to 70% of usual carmustine dose.</p>
<p style="text-indent:-2em;margin-left:6em;">If leukocytes &lt;2,000/mm<sup>3</sup> or platelets &lt;25,000/mm<sup>3</sup>: Reduce dose to 50% of usual carmustine dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Pulmonary toxicity (signs/symptoms or decreased carbon monoxide diffusing capacity):</b> Consider initiating systemic corticosteroid therapy (eg, prednisone) and consider discontinuing carmustine (Kalaycioglu 1995; Smith 1989).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Carmustine wafer: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intracranial hypertension (related to brain edema, inflammation, or necrosis of brain tissue surrounding resection): </b>May require re-operation to remove wafers (or remnants) for refractory cases.</p></div>
<div class="block doe drugH1Div" id="F146517"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F50023578"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13118" href="/d/html/13118.html" rel="external">see "Carmustine: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Children are at increased risk for pulmonary toxicity due to carmustine, weigh risk vs benefit before use. Carmustine IV is associated with a moderate or high emetic potential (dose related); antiemetics are recommended to prevent nausea and vomiting (POGO [Dupuis 2011]). Refer to individual protocols; dosing and frequency may vary.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9e22278f-fc37-45e9-a433-00ee2e498352">Brain tumors, myeloablative therapy prior to autologous stem cell rescue</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Brain tumors, myeloablative therapy prior to autologous stem cell rescue:</b> Very limited data available; Infants, Children, and Adolescents: IV: 100 mg/m<sup>2</sup>/dose twice daily for 3 days (total: 600 mg/m<sup>2</sup>) as part of a high dose combination chemotherapy regimen is most commonly reported in trials with mixed results (Dunkel 1998; Finlay 2008); however, a phase I trial identified a lower dose of 100 mg/m<sup>2</sup>/dose once daily for 3 days (total: 300 mg/m<sup>2</sup>) in combination with thiotepa as the maximum tolerated regimen with a high degree of pulmonary toxicity observed (Gilman 2011).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1b38f5b9-2280-4a60-a425-80486fe6bf43">Non-Hodgkin lymphoma; relapsed or resistant, high-dose chemotherapy prior to autologous bone marrow transplant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphoma; relapsed or resistant, high-dose chemotherapy prior to autologous bone marrow transplant:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">BEAM regimen: Adolescents ≥15 years: IV: 300 mg/m<sup>2</sup>/dose for 1 dose followed by etoposide, cytarabine, and melphalan (Mills 1995).</p>
<p style="text-indent:-2em;margin-left:4em;">CBV regimen: Children and Adolescents: IV: 100 mg/m<sup>2</sup>/dose once daily for 3 days (total dose: 300 mg/m<sup>2</sup>) on days -8 through -6 in combination with cyclophosphamide and etoposide (Harris 2011).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.</p>
<p style="text-indent:-2em;margin-left:4em;">Adult:</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic toxicity: Based on nadir counts with previous dose (manufacturer's labeling). IV:</p>
<p style="text-indent:-2em;margin-left:8em;">If leukocytes ≥3,000/mm<sup>3</sup> and platelets ≥75,000/mm<sup>3</sup>: Administer 100% of dose.</p>
<p style="text-indent:-2em;margin-left:8em;">If leukocytes 2,000 to 2,999/mm<sup>3</sup> or platelets 25,000 to 74,999/mm<sup>3</sup>: Administer 70% of dose.</p>
<p style="text-indent:-2em;margin-left:8em;">If leukocytes &lt;2,000/mm<sup>3</sup> or platelets &lt;25,000/mm<sup>3</sup>: Administer 50% of dose.</p></div>
<div class="block dorp drugH1Div" id="F51090253"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: There are no dosage adjustments provided in the manufacturer’s labeling; experience in adult patients suggests that dose should be reduced in renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F51090254"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution, dosage adjustment may be necessary.</p></div>
<div class="block adr drugH1Div" id="F146481"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Implant:</b></p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Central nervous system: Seizure (37%; new or worsening: 20%), cerebral edema (4% to 23%), depression (16%)</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Skin rash (5% to 12%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Nausea (22%), vomiting (21%), constipation (19%)</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Urinary tract infection (21%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Weakness (22%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Wound healing impairment (14% to 16%), fever (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Chest pain (5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Central nervous system: Intracranial hypertension (9%), cerebral hemorrhage (6%), meningitis (4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal pain (8%)</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Abscess (local 6%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Back pain (7%)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, flushing (with rapid infusion), occlusive arterial disease, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Brain disease, headache, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, burning sensation of skin, hyperpigmentation</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, diarrhea, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Gynecomastia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Acute leukemia, anemia, bone marrow dysplasia, leukemia, leukopenia (common; onset: 5 to 6 weeks; recovery: after 1 to 2 weeks), thrombocytopenia (common: onset: ~4 weeks; recovery: after 1 to 2 weeks)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase, increased serum bilirubin, increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Opportunistic infection</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Burning sensation at injection site, erythema at injection site, pain at injection site, swelling at injection site, tissue necrosis at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, conjunctival edema, conjunctival hemorrhage, ophthalmic signs and symptoms (loss of depth perception), suffusion of the conjunctiva (with rapid infusion)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Azotemia (progressive), nephron atrophy, renal failure</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pulmonary disease, pneumonitis, pulmonary fibrosis (occurring up to 17 years after treatment), pulmonary infiltrates</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Febrile neutropenia (Chopra 1993), sepsis (implant), venous thrombosis at injection site (IV)</p></div>
<div class="block coi drugH1Div" id="F146495"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Hypersensitivity to carmustine or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Implant: There are no contraindications listed in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): IV: Hypersensitivity to other nitrosoureas; pregnancy; breastfeeding.</p></div>
<div class="block war drugH1Div" id="F146477"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Carmustine IV causes bone marrow suppression, primarily thrombocytopenia (which may lead to bleeding) and leukopenia (which may cause infection). Hematologic toxicity is dose-limiting, may be severe, and is generally delayed and cumulative; thrombocytopenia is usually more severe than leukopenia. Myelosuppression generally occurs 4 to 6 weeks after administration; thrombocytopenia occurs at ~4 weeks and persists for 1 to 2 weeks; leukopenia occurs at 5 to 6 weeks and persists for 1 to 2 weeks. Anemia may occur (less common and less severe than leukopenia or thrombocytopenia).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic: Reversible increases in transaminases, bilirubin, and alkaline phosphatase have been reported (rare) with the IV formulation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion-site reactions: Rapid infusions are associated with skin flushing and conjunctiva redness (onset: &lt;2 hours; duration ~4 hours). Carmustine is also associated with injection-site burning and local tissue reactions, including swelling, pain, erythema, and necrosis, have been reported. Monitor infusion site closely for infiltration or injection-site reactions. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intracranial hypertension: Brain edema has been reported in patients with newly diagnosed glioma receiving wafer implants, including one report of intracranial mass effect unresponsive to corticosteroids that led to brain herniation. Intracranial hypertension may be related to brain edema, inflammation, or necrosis of brain tissue surrounding resection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Meningitis: Cases of meningitis have occurred in patients with recurrent glioma receiving wafer implants. Two cases were bacterial (one patient required removal of implants 4 days after implantation and the other developed meningitis following reoperation for recurrent tumor). Another case was determined to be chemical meningitis and resolved with corticosteroids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular toxicity: Investigational administration (intraarterial intracarotid route [not an approved route]) has been associated with ocular toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Carmustine IV is associated with dose-related pulmonary toxicity; patients receiving cumulative doses &gt;1,400 mg/m<sup>2</sup> are at significantly higher risk. Delayed onset of pulmonary fibrosis may occur years after treatment (may be fatal), particularly in children. Pulmonary toxicity has occurred in children and adolescents up to 17 years after treatment; this occurred in ages 1 to 16 for the treatment of intracranial tumors; cumulative doses ranged from 770 to 1,800 mg/m<sup>2</sup> (in combination with cranial radiotherapy). Pulmonary toxicity is characterized by pulmonary infiltrates and/or fibrosis and has been reported from 9 days to 43 months after nitrosourea treatment (including carmustine). Although pulmonary toxicity generally occurs in patients who have received prolonged treatment, pulmonary fibrosis has been reported with cumulative doses below 1,400 mg/m<sup>2</sup>. Interstitial fibrosis at lower doses has occurred (rare). In addition to high cumulative doses, other risk factors for pulmonary toxicity include history of lung disease and baseline predicted forced vital capacity (FVC) or carbon monoxide diffusing capacity (DLCO) &lt;70%. For high-dose treatment (transplant; off-label dose), acute lung injury may occur ~1 to 3 months post transplant; advise patients to contact their transplant physician for dyspnea, cough, or fever.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal: Renal failure, progressive azotemia, and decreased kidney size have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancies: Long-term IV use is associated with the development of secondary malignancies (acute leukemias and bone marrow dysplasias).</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Seizures occurred in patients who received carmustine wafer implants, including new or worsening (treatment-emergent) seizures. Just over half of treatment-emergent seizures occurred within 5 days of surgery; the median onset of first new or worsened post-operative seizure was 4 days. Optimal anti-seizure therapy should be initiated prior to surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">• Wound healing impairment: Impaired neurosurgical wound healing, including wound dehiscence, delayed healing, and subdural, subgaleal, or wound effusions may occur with carmustine wafer implant treatment; cerebrospinal fluid leaks have also been reported.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Children are at higher risk of delayed pulmonary toxicity with the IV formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Injection: Diluent may contain ethanol or propylene glycol (formulation-dependent; refer to manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">• Wafer: Monitor closely for known craniotomy-related complications (seizure, intracranial infection, abnormal wound healing, brain edema). Wafer migration may occur; avoid communication between the resection cavity and the ventricular system to prevent wafer migration; communications larger than the wafer should be closed prior to implantation; wafer migration into the ventricular system may cause obstructive hydrocephalus. Monitor for signs/symptoms of obstructive hydrocephalus.</p></div>
<div class="block foc drugH1Div" id="F146489"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">BiCNU: 100 mg (1 ea [DSC]) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea); 100 mg (1 ea); 300 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Wafer, Implant: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gliadel Wafer: 7.7 mg (8 ea) [contains polifeprosan 20]</p></div>
<div class="block geq drugH1Div" id="F146473"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F5100296"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Carmustine Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $1,127.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $662.04 - $4,481.09</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $6,765.03</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Wafer</b> (Gliadel Wafer Implant)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.7 mg (per each): $5,812.84</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866207"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">BiCNU: 100 mg (1 ea) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F146492"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Carmustine (IV) is associated with a high emetic potential; antiemetics are recommended to prevent nausea and vomiting (ASCO [Hesketh 2020]; MASCC/ESMO [Roila 2016]).</p>
<p style="text-indent:-2em;margin-left:2em;">Injection: Infuse slowly over at least 2 hours (infusions &lt;2 hours may lead to injection site pain or burning); infuse through a free-flowing saline or dextrose infusion, or administer through a central catheter to alleviate venous pain/irritation. Do not exceed a rate of 1.66 mg/m<sup>2</sup>/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">Irritant; infiltration may result in local pain, erythema, swelling, burning and skin necrosis; the alcohol-based diluent may be an irritant, especially with high doses. Avoid extravasation. Monitor infusion site.</p>
<p style="text-indent:-2em;margin-left:4em;">High-dose carmustine (transplant dose; off-label use): Infuse over a least 2 hours to avoid excessive flushing, agitation, and hypotension; was infused over 1 hour in some trials (Chopra 1993). <b>High-dose carmustine may be fatal if not followed by stem cell rescue.</b> Monitor vital signs frequently during infusion; patients should be supine during infusion and may require the Trendelenburg position, fluid support, and vasopressor support.</p>
<p style="text-indent:-2em;margin-left:2em;">Implant: Double glove before handling; outer gloves should be discarded as chemotherapy waste after handling wafers. Any wafer or remnant that is removed upon repeat surgery should be discarded as chemotherapy waste. The outer surface of the external foil pouch is not sterile. Open pouch gently; avoid pressure on the wafers to prevent breakage. Wafers that are broken in half may be used, however, wafers broken into more than 2 pieces should be discarded in a biohazard container. Slight overlapping of wafers during placement is acceptable. Oxidized regenerated cellulose (Surgicel) may be placed over the wafer to secure; irrigate cavity prior to closure.</p>
<p style="text-indent:-2em;margin-left:2em;">Topical (off-label use): Wear gloves during application. Apply solution with brush or gauze pads; ointment and solution should be applied to involved areas only; avoid contact with eyes/orifices (Zackheim 2003).</p></div>
<div class="block admp drugH1Div" id="F52612370"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Carmustine IV is associated with a moderate or high emetic potential (dose related); antiemetics are recommended to prevent nausea and vomiting (POGO [Dupuis 2011]).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Infuse over 2 hours (infusions &lt;2 hours may lead to injection site pain or burning); infuse through a free-flowing saline or dextrose infusion, or administer through a central catheter to alleviate venous pain/irritation. Significant absorption to PVC containers; should be prepared in either glass or polyolefin containers.</p>
<p style="text-indent:-2em;margin-left:4em;">High-dose carmustine (transplant dose): Infuse over at least 2 hours to avoid excessive flushing, agitation, and hypotension; was infused over 1 hour in some trials (Chopra 1993). High-dose carmustine may be fatal if not followed by stem cell rescue. Monitor vital signs frequently during infusion; patients should be supine during infusion and may require the Trendelenburg position, fluid support, and vasopressor support.</p></div>
<div class="block hazard drugH1Div" id="F49130925"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F146490"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Central nervous system tumors:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Injection: Palliative treatment of brain tumors including glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors.</p>
<p style="text-indent:-2em;margin-left:4em;">Wafer (implant): Treatment of newly-diagnosed high-grade glioma (as an adjunct to surgery and radiation); treatment of recurrent glioblastoma (as adjunct to surgery).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, relapsed/refractory:</b> Injection: Palliative treatment (secondary) of Hodgkin lymphoma (in combination with other antineoplastics) that has relapsed with or was refractory to primary therapy.</p></div>
<div class="block off-label drugH1Div" id="F25722051"><span class="drugH1">Use: Off-Label: Adult</span><p>Hematopoietic cell or bone marrow transplant (autologous) conditioning regimen; Mycosis fungoides, early stage (topical)</p></div>
<div class="block mst drugH1Div" id="F2136823"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carmustine may be confused with bendamustine, lomustine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298978"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F146483"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May enhance the myelosuppressive effect of Carmustine. Management: Consider alternatives to cimetidine in patients receiving carmustine. If the combination cannot be avoided, monitor for enhanced carmustine myelotoxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Carmustine may decrease the serum concentration of Fosphenytoin-Phenytoin.  Management: Consider alternatives to fosphenytoin-phenytoin in carmustine treated patients. If combined, monitor closely for reduced phenytoin concentrations and increase fosphenytoin-phenytoin doses as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melphalan: May enhance the adverse/toxic effect of Carmustine. Specifically, melphalan may sensitize patients to carmustine lung toxicity.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melphalan Flufenamide: May enhance the adverse/toxic effect of Carmustine. Specifically, melphalan flufenamide may sensitize patients to carmustine lung toxicity.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: May decrease the serum concentration of Carmustine. Management: Consider alternatives to phenobarbital when using carmustine. If combined, monitor for reduced carmustine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May decrease the serum concentration of Carmustine. Management: Consider alternatives to primidone when using carmustine. If combined, monitor for reduced carmustine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49295130"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to therapy. Patients who could become pregnant should use highly effective contraceptives during and for at least 6 months following treatment with carmustine. Patients with partners who could become pregnant should use highly effective contraceptives during and for at least 3 months following treatment with carmustine. Carmustine may impair male fertility; advise males of potential risk of infertility.</p></div>
<div class="block pri drugH1Div" id="F146498"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action, and data from animal reproduction studies, in utero exposure to carmustine may cause fetal harm. Outcome information related to the use of carmustine in pregnancy is limited (NTP 2013).</p></div>
<div class="block brc drugH1Div" id="F146499"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if carmustine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends breastfeeding be discontinued during treatment with the injection and for at least 7 days after implantation of the wafer.</p></div>
<div class="block mop drugH1Div" id="F146487"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Verify pregnancy status prior to therapy in patients who could become pregnant.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection: CBC with differential and platelet count (weekly for at least 6 weeks after each dose), pulmonary function tests (FVC, DL<sub>CO</sub>; at baseline and frequently during treatment), LFTs (transaminases and bilirubin; periodically during treatment), renal function tests (periodically). Monitor BP and vital signs during administration. Monitor infusion site for possible infiltration or injection-site reactions. Monitor for signs/symptoms of pulmonary toxicity and for development of secondary malignancies.</p>
<p style="text-indent:-2em;margin-left:2em;">Wafer: Monitor postoperatively for seizures, impaired neurosurgical wound healing, and signs/symptoms of meningitis, CNS infection, and obstructive hydrocephalus; monitor closely for intracranial hypertension related to brain edema, inflammation, or necrosis of brain tissue surrounding resection.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F146476"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Carmustine interferes with the normal function of DNA and RNA by alkylation and cross-linking the strands of DNA and RNA, and by possible protein modification; may also inhibit enzyme processes by carbamylation of amino acids in protein.</p></div>
<div class="block phk drugH1Div" id="F146494"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Wafer: Systemic absorption measurable for ~24 hours after insertion</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: IV: 3.3 L/kg; readily crosses blood-brain barrier producing CSF levels ≥50% of blood plasma levels; highly lipid soluble</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Rapidly hepatic; forms active metabolites</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV: 15 to 75 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Wafer: Systemic: ~3 hours after insertion</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: IV: Urine (~60% to 70%) within 96 hours; lungs (~10% as CO<sub>2</sub>)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F146500"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Bicnu | Bodacler | Consium</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Bcnu | Carmubris | Carmustin obvius | Carmustin waymade</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Bicnu | Carmustine Juno | Carmustine lupin | Carmustine medsurge | Gliadel | Gliadel wafer</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Nitrumon</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Bcnu | Carmustine Obvius</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Becenum | Gliadel | Nibisnu</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bicnu | Carm spal p | Carmustina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Bicnu | Carmustine Obvius | Carmustine tillomed | Carmustine zentiva</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Carmubris | Carmustin ratiopharm | Carmustin waymade | Carmustine Obvius | Gliadel</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Bicnu</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Bicnu | Carmubris | Caroma | Carustine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Bicnu | Carmustina accord | Carmustina obvius | Carmustina teva | Gliadel</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Becenun | Carmustine macure | Carmustine Obvius</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Bicnu | Carmustine Obvius | Gliadel</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Carmustine Obvius | Gliadel</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Bicnu | Carmubris | Carmustine/tillomed | Gliadel</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Gliadel</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bicnu | Carmustine Obvius | Carmustine zentiva</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Bicnu | Gliadel</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Consium</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bicnu | Carmustina | Carmustine Obvius</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Gliadel</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bicnu</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Bicnu | Carmustine zentiva | Consium</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Nitrumon</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Bicnu | Carmustine Obvius</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bicnu | Gliadel</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Carmuther | Carustine | Gliadel wafer</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Carmustine accord | Carmustine Obvius | Carmustine teva | Carmustine tillomed</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Becenun | Bicnu | Carmubris | Carmustine macure | Carmustine Obvius</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Bicnu</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Carmustina</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Bicnu</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Bicnu | Carmubris | Carmustine Obvius | Carmustine zentiva | Carmuther</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Bicnu | Gliadel</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Bicnu | Carmustina obvius | Carmustina teva | Gliadel</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Bicnu</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Bicnu</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Becenun | Carmustine macure | Carmustine Obvius</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Bcnu | Carmubris</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Carmustine zentiva</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Bicnu | Carustine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Bicnu</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bicnu | Carmuther | Gliadel wafer</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Bicnu | Carmustina fu</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Carmubris | Carmuther | Gliadel</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7383088">
<a name="7383088"></a>Aronin PA, Mahaley MS Jr, Rudnick SA, et al. Prediction of BCNU Pulmonary Toxicity in Patients With Malignant Gliomas. <i>N Engl J Med</i>. 1980;303(4):183-188.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/7383088/pubmed" id="7383088" target="_blank">7383088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21947834">
<a name="21947834"></a>Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2011;29(31):4189-4198. doi:10.1200/JCO.2010.34.4614<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/21947834/pubmed" id="21947834" target="_blank">21947834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18071290">
<a name="18071290"></a>Benekli M, Smiley SL, Younis T, et al. Intensive Conditioning Regimen of Etoposide (VP-16), Cyclophosphamide and Carmustine (VCB) Followed by Autologous Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin's Lymphoma. <i>Bone Marrow Transplant</i>. 2008;41(7):613-619.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/18071290/pubmed" id="18071290" target="_blank">18071290</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  BiCNU (carmustine) [prescribing information]. East Brunswick, NJ: Avet Pharmaceuticals Inc; November 2021.</div>
</li>
<li>
<div class="reference">
                  BiCNU (carmustine) [product monograph]. Ottawa, Ontario, Canada: Marcan Pharmaceuticals Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15477552">
<a name="15477552"></a>Brandes AA, Tosoni A, Amistà P, et al. How Effective is BCNU in Recurrent Glioblastoma in the Modern Era? A Phase II Trial. <i>Neurology</i>. 2004;63(7):1281-1284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/15477552/pubmed" id="15477552" target="_blank">15477552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24462742">
<a name="24462742"></a>Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biol Blood Marrow Transplant</i>. 2014;20(5):600-616. doi:10.1016/j.bbmt.2014.01.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/24462742/pubmed" id="24462742" target="_blank">24462742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Accord.1">
<a name="Accord.1"></a>Carmustine 50 mg and 300 mg [prescribing information]. Durham, NC: Accord Healthcare Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SteriMaxCAN.1">
<a name="SteriMaxCAN.1"></a>Carmustine 100 mg [product monograph]. Oakville, Ontario, Canada: SteriMax Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8443375">
<a name="8443375"></a>Chopra R, McMillan AK, Linch DC, et al. The Place of High-Dose BEAM Therapy and Autologous Bone Marrow Transplantation in Poor-Risk Hodgkin's Disease. A Single-Center Eight-Year Study of 155 Patients. <i>Blood</i>. 1993;81(5):1137-1145.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/8443375/pubmed" id="8443375" target="_blank">8443375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7386477">
<a name="7386477"></a>Colvin M, Hartner J, Summerfield M. Stability of Carmustine in the Presence of Sodium Bicarbonate. <i>Am J Hosp Pharm</i>. 1980;37(5):677-678.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/7386477/pubmed" id="7386477" target="_blank">7386477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7844600">
<a name="7844600"></a>Colwill R, Crump M, Couture F, et al. Mini-BEAM as Salvage Therapy for Relapsed or Refractory Hodgkin's Disease Before Intensive Therapy and Autologous Bone Marrow Transplantation. <i>J Clin Oncol</i>. 1995;13(2):396-402.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/7844600/pubmed" id="7844600" target="_blank">7844600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9525840">
<a name="9525840"></a>Dunkel IJ, Garvin JH Jr, Goldman S, et al. High Dose Chemotherapy With Autologous Bone Marrow Rescue for Children With Diffuse Pontine Brain Stem Tumors. Children's Cancer Group. <i>J Neurooncol</i>. 1998;37(1):67-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/9525840/pubmed" id="9525840" target="_blank">9525840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21465637">
<a name="21465637"></a>Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/21465637/pubmed" id="21465637" target="_blank">21465637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23512831">
<a name="23512831"></a>Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/23512831/pubmed" id="23512831" target="_blank">23512831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12692621">
<a name="12692621"></a>Durando X, Lemaire JJ, Tortochaux J, et al. High-Dose BCNU Followed by Autologous Hematopoietic Stem Cell Transplantation in Supratentorial High-Grade Malignant Gliomas: A Retrospective Analysis of 114 Patients. <i>Bone Marrow Transplant</i>. 2003;31(7):559-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/12692621/pubmed" id="12692621" target="_blank">12692621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11217179">
<a name="11217179"></a>Favier M, De Cazanove F, Coste A, et al. Stability of Carmustine in Polyvinyl Chloride Bags and Polyethylene-Lined Trilayer Plastic Containers. <i>Am J Health Syst Pharm</i>. 2001;58(3):238-241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/11217179/pubmed" id="11217179" target="_blank">11217179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26834241">
<a name="26834241"></a>Ferreri AJ, Illerhaus G. The role of autologous stem cell transplantation in primary central nervous system lymphoma. <i>Blood</i>. 2016;127(13):1642-1649. doi:10.1182/blood-2015-10-636340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/26834241/pubmed" id="26834241" target="_blank">26834241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18802947">
<a name="18802947"></a>Finlay JL, DHall G, Boyett JM, et al. Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children’s Oncology Group. <i>Pediatr Blood Cancer</i>. 2008;51:806-811.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/18802947/pubmed" id="18802947" target="_blank">18802947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12074689">
<a name="12074689"></a>Fleming AB, Saltzman WM. Pharmacokinetics of the Carmustine Implant. <i>Clin Pharmacokinet</i>. 2002;41(6):403-419.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/12074689/pubmed" id="12074689" target="_blank">12074689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18625886">
<a name="18625886"></a>Geisler CH, Kolstad A, Laurell A, et al; Nordic Lymphoma Group. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. <i>Blood</i>. 2008;112(7):2687-2693. doi:10.1182/blood-2008-03-147025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/18625886/pubmed" id="18625886" target="_blank">18625886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21744474">
<a name="21744474"></a>Gilman AL, Jacobsen C, Bunin N, et al. Phase I study of tandem high-dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: a pediatric blood and marrow transplant consortium study. <i>Pediatr Blood Cancer</i>. 2011;57:506-513.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/21744474/pubmed" id="21744474" target="_blank">21744474</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Gliadel (carmustine) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals LLC; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol.</i> 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20637881">
<a name="20637881"></a>Harris RE, Termuhlen AM, Smith LM, et al. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962. <i>Biol Blood Marrow Transplant</i>. 2011;17(2):249-258.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/20637881/pubmed" id="20637881" target="_blank">20637881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18166803">
<a name="18166803"></a>Illerhaus G, Müller F, Feuerhake F, Schäfer AO, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. <i>Haematologica</i>. 2008;93(1):147-148. doi:10.3324/haematol.11771<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/18166803/pubmed" id="18166803" target="_blank">18166803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7842781">
<a name="7842781"></a>Kalaycioglu M, Kavuru M, Tuason L, Bolwell B. Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU). <i>Chest</i>. 1995;107(2):482-487. doi:10.1378/chest.107.2.482<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/7842781/pubmed" id="7842781" target="_blank">7842781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22473593">
<a name="22473593"></a>Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. <i>Ann Oncol</i>. 2012;23(10):2670-2675. doi:10.1093/annonc/mds059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/22473593/pubmed" id="22473593" target="_blank">22473593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20684990">
<a name="20684990"></a>Kim JE, Lee DH, Yoo C, et al. BEAM or BuCyE High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma Patients: A Single Center Comparative Analysis of Efficacy and Toxicity. <i>Leuk Res</i>. 2011;35(2):183-187.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/20684990/pubmed" id="20684990" target="_blank">20684990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7859226">
<a name="7859226"></a>Kintzel PE, Dorr RT. Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function. <i>Cancer Treat Rev</i>. 1995;21(1):33-64. doi:10.1016/0305-7372(95)90010-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/7859226/pubmed" id="7859226" target="_blank">7859226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16565956">
<a name="16565956"></a>Kyle RA, Leong T, Li S, et al. Complete Response in Multiple Myeloma: Clinical Trial E9486, an Eastern Cooperative Oncology Group Study Not Involving Stem Cell Transplantation. <i>Cancer</i>. 2006;106(9):1958-1966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/16565956/pubmed" id="16565956" target="_blank">16565956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20201949">
<a name="20201949"></a>Linch DC, Yung L, Smith P, et al. Final Analysis of the UKLG LY02 Trial Comparing 6-8 Cycles of CHOP With 3 Cycles of CHOP Followed by a BEAM Autograft in Patients &lt;65 Years With Poor Prognosis Histologically Aggressive NHL. <i>Br J Haematol</i>. 2010;149(2):237-243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/20201949/pubmed" id="20201949" target="_blank">20201949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8722346">
<a name="8722346"></a>Mahendra P, Johnson D, Scott MA, et al. Peripheral Blood Progenitor Cell Transplantation: A Single Centre Experience Comparing Two Mobilisation Regimens in 67 Patients. <i>Bone Marrow Transplant</i>. 1996;17(4):503-507.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/8722346/pubmed" id="8722346" target="_blank">8722346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11328296">
<a name="11328296"></a>Martín A, Fernández-Jiménez MC, Caballero MD, et al. Long-Term Follow-Up in Patients Treated With Mini-BEAM as Salvage Therapy for Relapsed or Refractory Hodgkin's Disease. <i>Br J Haematol</i>. 2001;113(1):161-171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/11328296/pubmed" id="11328296" target="_blank">11328296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7884420">
<a name="7884420"></a>Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. <i>J Clin Oncol</i>. 1995;13(3):588-595. doi:10.1200/JCO.1995.13.3.588<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/7884420/pubmed" id="7884420" target="_blank">7884420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24736875">
<a name="24736875"></a>National Toxicology Program. NTP monograph: developmental effects and pregnancy outcomes associated with cancer chemotherapy use during pregnancy. <i>NTP Monogr</i>. 2013;(2):i-214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/24736875/pubmed" id="24736875" target="_blank">24736875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2370889">
<a name="2370889"></a>O'Driscoll BR, Hasleton PS, Taylor PM, et al. Active Lung Fibrosis Up to 17 Years After Chemotherapy With Carmustine (BCNU) in Childhood. <i>N Engl J Med</i>. 1990;323(6):378-382.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/2370889/pubmed" id="2370889" target="_blank">2370889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9118039">
<a name="9118039"></a>Oken MM, Harrington DP, Abramson N, et al. Comparison of Melphalan and Prednisone With Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone in the Treatment of Multiple Myeloma: Results of Eastern Cooperative Oncology Group Study E2479. <i>Cancer</i>. 1997;79(8):1561-1567.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/9118039/pubmed" id="9118039" target="_blank">9118039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10918425">
<a name="10918425"></a>Papadakis V, Dunkel IJ, Cramer LD, et al. High-Dose Carmustine, Thiotepa and Etoposide Followed by Autologous Bone Marrow Rescue for the Treatment of High Risk Central Nervous System Tumors. <i>Bone Marrow Transplant</i>. 2000;26(2):153-160.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/10918425/pubmed" id="10918425" target="_blank">10918425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1919637">
<a name="1919637"></a>Reece DE, Barnett MJ, Connors JM, et al. Intensive Chemotherapy With Cyclophosphamide, Carmustine, and Etoposide Followed by Autologous Bone Marrow Transplantation for Relapsed Hodgkin's Disease. <i>J Clin Oncol</i>. 1991;9(10):1871-1879.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/1919637/pubmed" id="1919637" target="_blank">1919637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20122270">
<a name="20122270"></a>Reithmeier T, Graf E, Piroth T, Trippel M, Pinsker MO, Nikkhah G. BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. <i>BMC Cancer</i>. 2010;10:30. doi:10.1186/1471-2407-10-30<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/20122270/pubmed" id="20122270" target="_blank">20122270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133. doi:10.1093/annonc/mdw270<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12182772">
<a name="12182772"></a>Selker RG, Shapiro WR, Burger P, et al; Brain Tumor Cooperative Group. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. <i>Neurosurgery</i>. 2002;51(2):343-355; discussion 355-357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/12182772/pubmed" id="12182772" target="_blank">12182772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2654964">
<a name="2654964"></a>Smith AC. The pulmonary toxicity of nitrosoureas. <i>Pharmacol Ther</i>. 1989;41(3):443-460. doi:10.1016/0163-7258(89)90125-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/2654964/pubmed" id="2654964" target="_blank">2654964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17106012">
<a name="17106012"></a>Trissel LA, Xu QA, Baker M. Drug Compatibility With New Polyolefin Infusion Solution Containers. <i>Am J Health-Syst Pharm</i>. 2006;63(23):2379-2382.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/17106012/pubmed" id="17106012" target="_blank">17106012</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference">
                  Weingart JD, Brem H. Carmustine Implants: Potential in the Treatment of Brain Tumors. <i>CNS Drugs</i>. 1996;4:263-269.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27151889">
<a name="27151889"></a>Whittaker S, Hoppe R, Prince HM. How I treat mycosis fungoides and Sézary syndrome. <i>Blood</i>. 2016;127(25):3142-3153. doi:10.1182/blood-2015-12-611830<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/27151889/pubmed" id="27151889" target="_blank">27151889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14686972">
<a name="14686972"></a>Zackheim HS. Topical carmustine (BCNU) in the treatment of mycosis fungoides. <i>Dermatol Ther.</i> 2003;16(4):299-302.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/14686972/pubmed" id="14686972" target="_blank">14686972</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9206 Version 357.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
